H.C. Wainwright assumed coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $60 price target The company has a a “platform-validated” mRNA innovator with near-term catalysts in rare disease that could materially re-rate the stock, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics’ Earnings Call Highlights Progress and Optimism
- Arcturus Therapeutics’ COVID-19 Vaccine Approved in Japan
- Arcturus Therapeutics price target lowered to $54 from $63 at Leerink
- Arcturus Therapeutics: Promising Prospects with ARCT-032 and Billion-Dollar Market Potential
- Positive Outlook and Buy Rating for Arcturus Therapeutics Amid Promising Pipeline Developments and Strong Financial Position